SciELO - Scientific Electronic Library Online

vol.26 número2Conocimiento sobre la COVID-19 y uso correcto de mascarilla en trabajadores de una universidad de Perú durante la pandemia: estudio transversal índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados




Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google


Archivos de Prevención de Riesgos Laborales

versión On-line ISSN 1578-2549


INGLES-TORRUELLA, Joan et al. Reactogenicity study of mRNA vaccines against COVID-19. Arch Prev Riesgos Labor [online]. 2023, vol.26, n.2, pp.106-126.  Epub 24-Jul-2023. ISSN 1578-2549.


To compare the reactogenicity between the types of mRNA Commirnaty® (Pfizer) and Spikevax® (Moderna) vaccines against COVID-19 in a healthcare population.


Cross sectional study of short-term adverse effects and their consequences (sick leave, limitations of daily life, etc.) after the administration of the first and second doses of both vaccines in professionals and students of a health institution. A questionnaire on symptoms and their consequences was administered seven days after each vaccination dose. The prevalence and 95% confidence interval (95%CI) were calculated. Differences between vaccines were quantified using the odds ratio (OR) and its 95%CI.


The questionnaire was completed by 1924 and 1170 healthcare providers (response rates 62.2% and 39.1%) after the first and second doses, respectively, of the Commirnaty® vaccine, and 410 (56.0%) and 107 (15.0%) of Spikevax®. After the first dose of Comirnaty®, 67.4% presented some adverse effect, and 76.1% for Spikevax® (OR 1.5 95%CI 1.2-1.9). In general, women and young people showed greater reactogenicity and differences between vaccines. Consequences of adverse effects were more frequent for Spikevax®. The reactogenicity was higher after the second than the first dose, for both vaccines (Comirnaty®: 67.4% vs. 75.6%; Spikevax®: 76.1% vs. 87.9%.


The greater reactogenicity and its consequences, for the first and second dose of the Spikevax® vaccine compared to Comirnaty®, and of the second dose compared to the first dose of both vaccines, provides useful knowledge for planning vaccination against COVID-19 campaigns in healthcare settings.

Palabras clave : SARS-CoV-2; COVID-19-vaccination; mRNA vaccines; adverse reactions; health care workers.

        · resumen en Español     · texto en Español     · Español ( pdf )